CardioExchange Archive

March 24th, 2014

Selections from Richard Lehman’s Literature Review: March 24th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include non-leg venous thrombosis in critically ill adults, a comparison of factor Xa inhibitors and warfarin for preventing stroke and thromboembolism in atrial fibrillation, and more.

---

December 5th, 2013

Large Study Finds Favorable Risk-Benefit Profile for the New Anticoagulants

Larry Husten, PHD

A very large new meta-analysis finds a favorable risk-benefit for the new oral anticoagulant drugs in the setting of atrial fibrillation. The findings, published online in the Lancet, were remarkably consistent for all four of the new agents which have been fighting to replace warfarin, which was the only oral anticoagulant available for decades until the arrival of […]

---

September 18th, 2013

Is Edoxaban the Most Promising of the Novel Anticoagulants?

Samuel Goldhaber, MD

Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.

---

November 13th, 2011

ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients

Larry Husten, PHD

Results of the highly anticipated ATLAS-ACS 2–TIMI 51 trial demonstrate that ACS patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor Xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome  trial was […]

---

July 24th, 2011

APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS

Larry Husten, PHD

A large phase 3 trial of an investigational factor Xa inhibitor, when added to antiplatelet therapy in ACS patients, was stopped early because of bleeding complications.

---

November 1st, 2010

ROCKET AF: Is Rivaroxaban Ready for Blast Off?

Harlan M. Krumholz, MD, SM

With the approval of dabigatran and now the preliminary and partial results of ROCKET AF, we’ll  need to be familiar with much more than just warfarin to address the anticoagulation needs of our patients. The early word on ROCKET AF, which will be presented at AHA, is that rivaroxaban is at least as effective as warfarin […]

---